Drug Database
ES

esmolol hydrochoride

✓ Approved

HQ Specialty Pharma · ADRB1 · 小分子

什么是 esmolol hydrochoride?

esmolol hydrochoride 是一种小分子,由HQ Specialty Pharma研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

公司HQ Specialty Pharma
药物类别小分子
分子靶点ADRB1
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

esmolol hydrochoride 作用于 1 个分子靶点:

ADRB1adrenoceptor beta 1 (B1AR, RHR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

esmolol hydrochoride 针对 3 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Cardiac disordersAtrial fibrillation✓ Approved
Vascular disordersHypertension✓ Approved
Cardiac disordersSupraventricular tachycardia✓ Approved

相关研究文献

PubMedFrontiers in physiology2026-09-09

Ea/Ees and oscillatory power fraction capture complementary but distinct components of ventriculoarterial coupling: a porcine study.

Flade Hans Martin HM, Kirkeby-Garstad Idar I, Lyng Oddveig O, Tannvik Tomas Dybos TD et al.

Ventriculoarterial coupling (VAC), traditionally assessed using the invasive "gold standard" Ea/Ees ratio (arterial elastance to end-systolic elastance), is clinically important but requires approximations that are impractical at the bedside. Oscillatory power fraction (OPF), defined as the ratio of oscillatory to total hydraulic power and derived from synchronized aortic flow-pressure measurements, has been proposed as a pragmatic VAC surrogate. This study aimed to clarify the possible correlation between VAC and OPF in pharmacologically induced hemodynamic extremes. In 14 juvenile pigs challenged with vasoactive (phenylephrine, nitroprusside) and cardioactive drugs (dobutamine, esmolol) titrated toward protocolized targets (± 40% MAP, ± 50% dP/dt), we obtained a comprehensive dataset using intracardiac conductance catheters, intraaortic pressure probes, and ascending aortic flow probes. Linear mixed models with animal as a random effect compared baseline and drug-effect states. The coupling of the two responses was assessed from each animal's baseline-to-effect change, corrected for measurement error estimated from the replicate recordings. Ea/Ees changed by 10%-36% across the four interventions, whereas OPF changed by 1.5%-12%, and under phenylephrine and dobutamine, the change in OPF was negligible (|d| < 0.2, both p > 0.2) despite measurable changes in Ea/Ees. Esmolol was the only challenge under which both indices changed substantially in the same direction (Ea/Ees: + 35.4%, OPF: + 12.2%). Whether the magnitudes of the two responses were coupled could not be determined. Dobutamine markedly increased Ees, total power, and oscillatory power while preserving OPF despite a reduction in Ea/Ees, indicating improved VAC but stable pulsatile efficiency. Vasoactive drugs (phenylephrine, nitroprusside) substantially altered Ea/Ees without relevant OPF changes. Ea/Ees and OPF are not interchangeable. OPF responded far less strongly than Ea/Ees to the loading changes imposed here and did not resolve them under two of the four challenges. This is consistent with the two indices reflecting predominantly steady and pulsatile aspects of arterial load, although the present data do not demonstrate that separation directly. While OPF cannot replace Ea/Ees, power-derived indices offer practical adjuncts for characterizing ventriculoarterial interactions and the effects of selected drugs at the intensive care bedside.

PMID 42712720
阅读全文 →
PubMedAnesthesiology research and practice2026-08-30

Intraoperative Hemodynamic Management and Cerebral Protection During Awake Craniotomy: Evidence-Based Approaches.

Maragh Marc Knezevic MK, Garcia Alanna Pagan AP, Oliinyk Yuliia Y, Acharjee Jayottri J et al.

Awake craniotomy is a standard neurosurgical technique that enables real-time assessment of brain functions during tumor resection, with high success rates. Although highly effective, the procedure is associated with hemodynamic disturbances, including blood pressure variability and impaired cerebral perfusion, compromising intraoperative safety. A focused literature search of PubMed, Embase, and Google Scholar was performed to identify relevant studies on intraoperative hemodynamic management during awake craniotomy. Findings were synthesized narratively to summarize current evidence, highlight emerging strategies, and identify knowledge gaps. Hypertension (8%-34%) was the most common disturbance, often triggered by painful surgical stimuli or emergence from sedation, with repeat craniotomy, impaired autoregulation, and glioma pathology as additional risk factors. Hypotension (10%-11%) was linked to perioperative stroke and mortality. Cerebral hypoperfusion contributed to poor outcomes, with stroke up to 23% and neurological morbidity in 68% of patients. Preventive strategies, such as scalp blocks, individualized blood pressure targets, and the use of dexmedetomidine and midazolam, improved intraoperative stability, while short-acting agents, including esmolol and labetalol, were preferred for rapid control. Advanced monitoring modalities, including arterial lines, near-infrared spectroscopy, and cerebral autoregulation indices, enhance safety and support accurate functional mapping. Hemodynamic instability during awake craniotomy influences outcomes. Current evidence supports multimodal prevention, tailored blood pressure control, and short-acting pharmacological agents; practice variation and the lack of randomized trials limit standardization. Looking ahead, advanced monitoring and emerging AI systems may provide new opportunities to enhance cerebral protection and optimize patient safety. This review summarizes evidence on intraoperative hemodynamic control in awake craniotomy, emphasizing strategies that enable maximal safe resection while preserving neurological function.

PMID 42668949
阅读全文 →
PubMedWorld journal of methodology2026-08-21

Comparison of propofol alone vs propofol-phenylephrine combination for intraoperative hemodynamic stability in glioma surgery.

Thotungal Rhea R, Kaushal Ashutosh A, Agrawal Amit A, Jain Anuj A et al.

Propofol is widely used for induction in glioma surgery for its neuroprotective effects and favorable recovery profile. However, its dose-dependent hypotension is a major limitation in procedures requiring stable cerebral perfusion. To compare the efficacy of propofol vs propofol-phenylephrine (PPE) combination in maintaining hemodynamic stability in patients undergoing glioma surgery. Ninety American Society of Anesthesiologists I-II patients scheduled for elective glioma surgery were randomized to receive either propofol (group P) or a PPE admixture (group PPE). Induction was performed with slow titration of the study drug until loss of verbal response and Bispectral index < 60, followed by a continuous infusion (50 μg/kg/minute) until skin closure. Hemodynamic parameters [mean arterial pressure (MAP), systolic blood pressure, diastolic blood pressure, and heart rate] were recorded at baseline, during induction, immediately after intubation, and at predefined intraoperative time points. The incidence of hypotension, vasopressor and esmolol use, and brain relaxation scores were compared. Group PPE demonstrated significantly better preservation of MAP, systolic blood pressure, diastolic blood pressure, and heart rate throughout the peri-induction and intraoperative periods (P < 0.05). The mean maximum MAP reduction during induction was greater in group P compared with group PPE (19.7 mmHg vs 12.5 mmHg; P < 0.01). Hypotensive episodes were significantly more frequent in group P than in group PPE (84.4% vs 6.7%; P < 0.001). Rescue phenylephrine requirements were markedly lower in group PPE (P < 0.001). Esmolol use and brain relaxation scores were comparable between groups. Adding phenylephrine to propofol for induction and maintenance provides superior hemodynamic stability without compromising brain relaxation in glioma surgery.

PMID 42626261
阅读全文 →
PubMedAcute and critical care2026-08-19

Esmolol in the management of refractory ventricular fibrillation: a systematic review and meta-analysis.

Lau Kathleen K, Chau Yau-Lam Alex YA, Cheng Ting-An TA, Lai Michael M et al.

Refractory ventricular fibrillation (rVF) presents a significant challenge in advanced cardiovascular life support (ACLS), with traditional antiarrhythmics showing limited success in improving long-term survival and neurological function. Esmolol, a beta-1 selective adrenergic receptor antagonist, might offer benefits due to its rapid onset and catecholamine-suppressing effects during cardiac arrest. This systematic review and meta-analysis (SRMA) evaluates the effectiveness of esmolol in improving the temporary return of spontaneous circulation (ROSC), sustained ROSC, survival to discharge, and survival to discharge with favorable neurological outcomes in rVF patients. This SRMA reviewed Medline (Ovid), Embase (Ovid), and Cochrane Central (Ovid) from their inception until October 2, 2025, for full-text clinical or observational studies assessing esmolol use alongside standard ACLS in adult rVF in both prehospital and in-hospital settings. The risk of bias was independently assessed using the Newcastle-Ottawa Scale. Pooled risk ratios (RRs; 95% CI) are reported. Analyses in which I² >50% used a random-effects model; otherwise, a common-effect model was used. Four studies (n=273) are included. Esmolol was associated with an increased temporary ROSC (RR, 1.80; 95% CI, 1.09-2.98), and although the links were not statistically significant, esmolol trended toward a benefit in sustained ROSC (RR, 1.25; 95% CI, 0.28-5.66), survival to discharge (RR, 1.08; 95% CI, 0.57-2.03), and survival to discharge with favorable neurological outcomes (RR, 2.08; 95% CI, 0.83-5.24). Esmolol was associated with improved temporary ROSC in rVF. The sensitivity analysis suggests potential benefits for sustained ROSC and neurological survival, but more data are needed. Further research is needed to clarify its role.

PMID 42613868
阅读全文 →
PubMedJournal of clinical medicine2026-08-13

Protective Effect of Esmolol on the Hypertensive Aortic Wall Persists After Withdrawal of Short-Term Treatment.

Fernández-Morales David D, Arnalich-Montiel Ana A, Delgado-Martos María J MJ, Rodríguez-Rodríguez Pilar P et al.

Background: Our research group has previously demonstrated the protective effect of short-term treatment with esmolol on large artery remodeling. However, whether this beneficial effect persists after treatment withdrawal remains unknown. Therefore, the aim of the present study was to investigate whether regression of thoracic aorta remodeling after a short-term esmolol treatment persists following drug withdrawal. Methods: Adult male spontaneously hypertensive rats (SHRs) received either esmolol (300 µg/kg/min) or vehicle (saline solution) by continuous infusion for 48 h. Following treatment, animals were evaluated either immediately (SHR-E 48 h group) or after withdrawal periods of 7 days (SHR-E 7 d group) or 1 month (SHR-E 1 m group). Hemodynamic parameters, thoracic aorta geometry, extracellular matrix composition (elastin and collagen), and the passive mechanical response of the arterial wall (β parameter) were assessed in all animals. Results: Forty-eight hours of esmolol treatment significantly reduced blood pressure and attenuated thoracic aortic wall thickness, external diameter, cross-sectional area, collagen content and elastic fiber density. Additionally, passive mechanical testing showed a significant reduction in the β parameter, indicating improved arterial compliance after treatment. Remarkably, these structural and mechanical benefits persisted for up to one month after withdrawal, despite the return of blood pressure to hypertensive levels. Conclusions: Protective effect of esmolol on aortic remodeling is persistent after treatment withdrawal in SHRs, perhaps independent of blood pressure.

PMID 42589903
阅读全文 →
PubMedAnesthesia and analgesia2026-08-11

Esmolol and Opioid Sparing: Analgesic Signal or Hemodynamic Silhouette?

Mistry Tuhin T, Nair Abhijit Sukumaran AS

PMID 42575132
阅读全文 →

注册免费账户还可查看另外 1635 篇文献

免费注册查看全部文献 →

了解更多esmolol hydrochoride